中国智造MitralStitch二尖瓣修复系统 为中亚古国带来“心”希望

2019-09-16 不详 美通社

“一带一路”倡议提出5年多来,沿线国家的医疗合作在古老的丝绸之路上重新焕发出新的生机。乌兹别克斯坦是中国的友好邻邦,古“丝绸之路”在两千多年前就把两国和两国人民紧密地联系在一起。而今,来自中国智造的经导管二尖瓣瓣膜修复系统为这个中亚古国带去了该领域的国际尖端技术,翻开了中亚心血管疾病治疗史的新篇章。 乌兹别克斯坦共和国建国28周年之际,受乌兹别克斯坦国家心血管中心的邀请,中国医学科学院阜

“一带一路”倡议提出5年多来,沿线国家的医疗合作在古老的丝绸之路上重新焕发出新的生机。乌兹别克斯坦是中国的友好邻邦,古“丝绸之路”在两千多年前就把两国和两国人民紧密地联系在一起。而今,来自中国智造的经导管二尖瓣瓣膜修复系统为这个中亚古国带去了该领域的国际尖端技术,翻开了中亚心血管疾病治疗史的新篇章。

乌兹别克斯坦共和国建国28周年之际,受乌兹别克斯坦国家心血管中心的邀请,中国医学科学院阜外医院潘湘斌教授携首个中国智造的MitralStitch(R)二尖瓣瓣膜修复系统在塔什干当地时间9月2日成功完成了MitralStitch(R)系统的海外首例临床应用手术,获得了国内NMPA确证性临床研究成功启动后的再一次重大突破。

乌兹别克斯坦撒马尔罕,不仅是中亚最古老的城市之一,更是古丝绸之路的重要枢纽。乌兹别克斯坦心血管疾病多发,40-64岁人群中近20%面临心血管疾病风险,平均每年有150万急慢性心血管病例,心血管疾病及其他非传染病每年花费国家预算达9.3万亿苏姆(1美元约合8290苏姆)。乌兹别克斯坦共和国建国28周年之际,受乌兹别克斯坦国家心血管中心的邀请,中国医学科学院阜外医院潘湘斌教授携首个中国智造的MitralStitch®二尖瓣瓣膜修复系统在塔什干当地时间9月2日成功完成了MitralStitch®系统的海外首例临床应用手术,获得了国内NMPA确证性临床研究成功启动后的再一次重大突破。此例手术也是中亚地区首例经导管二尖瓣微创修复案例,推动了中亚地区二尖瓣治疗领域的发展。以MitralStitch®二尖瓣瓣膜修复系统为代表的中国智造的创新医疗技术在“一带一路”的传播和应用,不仅链接了民心相通,更连接了生命的希望。

中为中国阜外医院潘湘斌教授 左为Sharipov教授
中为中国阜外医院潘湘斌教授 左为Sharipov教授

二尖瓣反流是最为常见的心脏瓣膜疾病,微创二尖瓣介入治疗技术将为广大中重度二尖瓣反流患者带来福音和希望。秉承创新研发颠覆式技术的理念,德晋医疗联合国内顶尖心血管中心组成产学研攻关小组,汇聚临床专家与工程师团队,成功研发出国内首款用于二尖瓣反流微创治疗手术的MitralStitch®二尖瓣瓣膜修复系统。MitralStitch®二尖瓣瓣膜修复系统设计理念来源于成熟外科术式,以微创的方式实现了外科二尖瓣的生理性修复,且无需射线辅助,仅在超声引导下,即可完成人工腱索植入及缘对缘修复,一套器械可行两种手术方式提供三套临床解决方案,且与同类竞品相比,不改变二尖瓣生理结构,保留了后续介入治疗的可能性。

本次接受手术的患者术前被诊断为二尖瓣脱垂致重度反流,潘湘斌教授与乌方Sharipov教授在术前深入讨论交流,为此例患者制订了详尽的治疗计划,潘教授向乌方医生及患者家属介绍了MitralStitch®二尖瓣瓣膜修复系统的特点及治疗方式。术中,潘湘斌教授于患者肋骨间切开3-4cm小口,在单纯超声引导下植入人工腱索,器械操作仅耗时数分钟。术后即刻原本大量的二尖瓣反流完全消失,患者症状明显改善。本例患者使用MitralStitch®系统进行腱索生理性修复后,保留了患者瓣膜自然解剖状态以及经导管进一步介入治疗的可能性。Sharipov教授对于这项来自中国的二尖瓣微创治疗技术的创新性和先进性表示由衷地赞叹,乌方观摩医生也对于该修复系统的便捷性、安全性和有效性进行了热烈讨论。术后患者家属特意等候在手术室外,对来自中国的潘湘斌教授表达了深切的感激之情,潘教授向家属详细介绍了手术的顺利经过和优异的疗效,以及与传统外科手术相比,微创介入治疗的先进性和优越性。

潘湘斌教授手术演示中
潘湘斌教授手术演示中

潘湘斌教授走过许多“一带一路”国家,开展新技术、传授新知识,提高了当地基层医院心血管疾病治疗水平。应乌兹别克斯坦国家心血管中心邀请,潘教授2018年起赴乌进行医学交流,传授和推广超声引导经皮介入技术 (PAN procedure),为15名患儿施行了先心封堵手术,术中使用单纯超声引导,避免了射线和造影剂注入,经患儿大腿根部穿刺小孔植入封堵器堵闭心脏缺损,实现了真正意义上的微创和无辐射手术治疗,过程顺利并取得了优异疗效。6个月后这些患儿心功能将得以康复,在健康状态下茁壮成长。“除了我们自己直接去救治病人,我们也将会给当地的医生进行培训,授人以鱼也授之以渔,从而挽救更多的生命。”潘湘斌教授接受当地电视台采访说“医疗创新就像音乐一样,没有国界之分,未来能够从MitralStitch®受益的远不只是中国患者,而是来自全球的更广泛的患者群体。”这项中国智造二尖瓣瓣膜修复产品具有完全自主知识产权并获得多项专利,是真正的中国技术,更是全球二尖瓣反流病患治疗的新选择。期待MitralStitch®二尖瓣瓣膜修复系统为二尖瓣反流患者带来更加安全有效的微创介入治疗“中国方案”,让中国智造,惠及世界。

潘湘斌教授与二尖瓣手术患者家属合影
潘湘斌教授与二尖瓣手术患者家属合影

文化是多样的,文明是多彩的,加强文明对话和文化交流,是构建人类命运共同体的最佳方案之一近年来,中国与乌兹别克斯坦的合作十分亮眼。中乌贸易连续两年保持30%以上的增速,中国继续保持乌第一大贸易伙伴国地位,基础设施建设蓬勃发展,人文交流密切。2016年,中乌关系提升为全面战略伙伴关系,共建“一带一路”成为中乌合作的亮点和主线,双方各领域合作驶入快车道。医疗合作是“一带一路”建设重要领域,关系到千百万人的生命和健康,同人类福祉息息相关。2016年6月,国家相关领导人对乌兹别克斯坦进行国事访问期间在乌最高会议立法院演讲提出打造“健康丝绸之路”,强调要着力深化“一带一路”沿线各国医疗卫生合作,加强在传染病疫情通报、疾病防控、医疗救援、传统医药领域互利合作,为中国同包括乌兹别克斯坦在内的世界各国加强医疗卫生合作指明了方向。

近年来,中乌两国在医疗卫生领域合作加速推进,亮点纷呈。德诺集团将携德晋医疗继续积极响应一带一路医疗建设,与国家心血管病中心建立合作项目,帮助一带一路沿线国家的医护人员学习和应用结构性心脏病治疗领域的先进医疗创新技术,通过医学交流挽救更多的海外患者,促进民心相通。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1657222, encodeId=68e0165e222c5, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Oct 23 12:18:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900865, encodeId=5a541900865b7, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sat Nov 16 06:18:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735692, encodeId=21da1e356927f, content=<a href='/topic/show?id=be5123894c6' target=_blank style='color:#2F92EE;'>#二尖瓣修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23894, encryptionId=be5123894c6, topicName=二尖瓣修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2033947151, createdName=fengyi823, createdTime=Wed Jun 24 11:18:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463264, encodeId=c162146326451, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Wed Sep 18 13:18:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372825, encodeId=49b43e2825a3, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Sep 17 05:53:30 CST 2019, time=2019-09-17, status=1, ipAttribution=)]
    2019-10-23 bsmagic9140
  2. [GetPortalCommentsPageByObjectIdResponse(id=1657222, encodeId=68e0165e222c5, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Oct 23 12:18:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900865, encodeId=5a541900865b7, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sat Nov 16 06:18:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735692, encodeId=21da1e356927f, content=<a href='/topic/show?id=be5123894c6' target=_blank style='color:#2F92EE;'>#二尖瓣修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23894, encryptionId=be5123894c6, topicName=二尖瓣修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2033947151, createdName=fengyi823, createdTime=Wed Jun 24 11:18:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463264, encodeId=c162146326451, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Wed Sep 18 13:18:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372825, encodeId=49b43e2825a3, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Sep 17 05:53:30 CST 2019, time=2019-09-17, status=1, ipAttribution=)]
    2019-11-16 gracezdd
  3. [GetPortalCommentsPageByObjectIdResponse(id=1657222, encodeId=68e0165e222c5, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Oct 23 12:18:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900865, encodeId=5a541900865b7, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sat Nov 16 06:18:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735692, encodeId=21da1e356927f, content=<a href='/topic/show?id=be5123894c6' target=_blank style='color:#2F92EE;'>#二尖瓣修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23894, encryptionId=be5123894c6, topicName=二尖瓣修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2033947151, createdName=fengyi823, createdTime=Wed Jun 24 11:18:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463264, encodeId=c162146326451, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Wed Sep 18 13:18:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372825, encodeId=49b43e2825a3, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Sep 17 05:53:30 CST 2019, time=2019-09-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1657222, encodeId=68e0165e222c5, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Oct 23 12:18:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900865, encodeId=5a541900865b7, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sat Nov 16 06:18:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735692, encodeId=21da1e356927f, content=<a href='/topic/show?id=be5123894c6' target=_blank style='color:#2F92EE;'>#二尖瓣修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23894, encryptionId=be5123894c6, topicName=二尖瓣修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2033947151, createdName=fengyi823, createdTime=Wed Jun 24 11:18:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463264, encodeId=c162146326451, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Wed Sep 18 13:18:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372825, encodeId=49b43e2825a3, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Sep 17 05:53:30 CST 2019, time=2019-09-17, status=1, ipAttribution=)]
    2019-09-18 wwzzly
  5. [GetPortalCommentsPageByObjectIdResponse(id=1657222, encodeId=68e0165e222c5, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Oct 23 12:18:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900865, encodeId=5a541900865b7, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Sat Nov 16 06:18:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735692, encodeId=21da1e356927f, content=<a href='/topic/show?id=be5123894c6' target=_blank style='color:#2F92EE;'>#二尖瓣修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23894, encryptionId=be5123894c6, topicName=二尖瓣修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2033947151, createdName=fengyi823, createdTime=Wed Jun 24 11:18:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463264, encodeId=c162146326451, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Wed Sep 18 13:18:00 CST 2019, time=2019-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372825, encodeId=49b43e2825a3, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Tue Sep 17 05:53:30 CST 2019, time=2019-09-17, status=1, ipAttribution=)]
    2019-09-17 yjs木玉

    好好好好好好

    0